Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Events Perspective
- On the Competitive Front: Biotech Balances Bankruptcies, Bailouts - and,
Soon, Boons
- On the Economic Front: Healthcare Features of the Stimulus Package
- Comparative Effectiveness Research
- NIH Funding
- Other
- On the Approvals Front: FDA' s First “Pharm” Animal Drug
Approval
- Deals Perspective
- Mergers & Acquisitions
- Notable Product-Related Deals
- Therapy-Area Deals - Focus on Oncology
- Biologics Continue to Be a Dealmaking Focus
- Biosimilars
- Stem Cells
- Other Notable Biologics Activity
- Pharmacogenomics/Biomarkers/Diagnostics
- Technology Deals
- Generics Perspective: Today' s Economy Presents the Industry with
Opportunities and Challenges
- Actavis and Ratiopharm for Sale
- Layoffs at Ratiopharm, Teva, and Pliva
- Teva and Momenta Aim to Make History with U.S. Biosimilar Approvals
- Obama Paves the Way for a Biosimilars Mechanism
- Strategy Perspective
- Return of the Mega-Consolidation
- Healthcare Policy: Inside Looking Out or Outside Looking In?
- GlaxoSmithKline in the Developing World: The Price Is Right?
Expert Commentary
- Biotech Investment Trends: The Quest for Capital
Tables
- 1. National Institutes of Health Challenge Grant Areas and Sample Topics
- 2. Select Transgenic Animal Drug Development Programs
- 3. Top Company Dealmaking Activity, Q1 2009
- 4. Top 20 Pharmaceutical Companies, by 2008 Pharmaceutical Sales, Pre- and
Post-Mega-Mergers
- 5. Select Therapy-Area Deals, Q1 2009
- 6. Select Biologics-Related Deals, Q1 2009
- 7. Select Oncology Pharmacogenomics/Biomarker/Diagnostics-Related Deals,
Q1 2009
- 8. Record of the European Medicine Association' s MAA Procedures
- 9. Decision Resources Analyst Opinion: Perspectives on Teva' s G-CSF
Biosimilars Initiative
- in the United States
- 10. Summary of U.S. Biosimilars Legislation
Figures
- 1. Biotech Quarterly Initial Public Offerings and Venture Capital
Investments, 2002-2008
- 2. First-Quarter 2009 U.S. Drug Approval Tallies and Highlights
- 3. Number of First-Quarter Deals, 2006-2009
- 4. Pharma and Biotech Deals Valued at More Than $100 Million in the First
Quarter of Each Year, 2006-2009
- 5. Three Deals, More Than $150 Billion Spent: Pfizer/Wyeth,
Roche/Genentech, and Merck & Co./ Schering-Plough, Q1 2009
- 6. Select Mergers & Acquisitions Valued at More Than $100 Million, Q1 2009
- 7. Select Pharma and Biotech Product-Related Deals Valued at More Than $2
Million, Q1 2009
- 8. Percentage of Deals by Therapeutic Area, Q1 2009
- 9. Percentage of Deals by Technology Type, Q1 2009
- 10. Select Financial Results for Teva, 2007 and 2008
- 11. Corporate Evolution of Pfizer
- 12. Dates of Patent Expiry for Pfizer' s Blockbuster Drugs
- 13. Dates of Patent Expiry for Wyeth' s Leading Drugs
- 14. Dates of Patent Expiry for Merck and Schering-Plough' s Leading Drugs
|
Related Report
|
View Cart
